Procedural pain management in the treatment of scleroderma digital ulcers (DU). There is valuable control of procedural pain during DU debridement with sequential, combined analgesic treatment. PubMed, Clin Exp Rheumatol, 12/22/2014. (Also see Treatments for Digital Ulcers)
Demographic and clinical features of systemic sclerosis (SSc) patients with anti-RNA polymerase III antibodies (RNAP). Measurement of RNAP in SSc patients is useful for the diagnosis and risk stratification of severe manifestation, such as renal crisis and severe skin sclerosis. PubMed, J Dermatol, 12/06/2014. (Also see Antibodies in Systemic Scleroderma)
Interleukin (IL)-17A promotes functional activation of systemic sclerosis (SSc) patient-derived dermal vascular smooth muscle cells by extracellular regulated protein kinases signaling pathway. IL-17A-derived from patients with SSc might be promising therapeutic targets for the treatment of SSc-related vasculopathy. PubMed, Arthritis Res Ther, 2014 Dec 31;16(6):4223. (Also see Interleukin-17 and Scleroderma)
Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis. Increased chemerin expression in dermal blood vessels may be associated with the development of digital ulcers in SSc. PubMed, 12/23/2014. (Also see Endothelin and Systemic Scleroderma)
Survival of adults with systemic sclerosis following lung transplantation: A nationwide cohort study. A diagnosis of SSc may confer an increased risk of death 1 year following lung transplantation compared to a diagnosis of ILD, but this risk is similar to that of PAH, a widely accepted indication for lung transplantation. PubMed, Arthritis Rheumatol, 01/07/2015. (Also see Lung Transplants)
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis(SSc). In the absence of pulmonary hypertension, diffusing capacity for carbon monoxide provides the best overall estimate of high-resolution computed tomography-measured lung disease. PubMed, Ann Rheum Dis, 12/01/2014. (Also see Pulmonary Fibrosis Diagnosis)
Rituximab in diffuse cutaneous systemic sclerosis (SSc): should we be using it today? We summarize the therapeutic use of rituximab in SSc and the basic science evidence suggesting that B cells and autoantibodies are the primary drivers of fibrosis in skin and lung tissue. PubMed, Rheumatology (Oxford), 07/01/2015. (Also see Causes of Scleroderma: B Cells and T Cells and Scleroderma Clinical Trials)
Three cases of bullous morphea: histopathologic findings with implications regarding pathogenesis. All of our cases showed hemorrhagic content in the bullae, which suggests local trauma as a mechanism involved in bulla formation. PubMed, J Cutan Pathol, 11/04/2014. (Also see Rare Types of Morphea)
Undifferentiated Connective Tissue Disease at risk for Systemic Sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc). This nosographic approach is instrumental to plan future studies devoted to investigate validated biomarkers heralding the development of major vascular disease manifestations as well as skin and/or organ fibrosis in patients at risk. PubMed, Autoimmun Rev, 11/18/2014. (Also see Undifferentiated Connective Tissue Disease)
Myofibroblasts in cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. There is a novel link between intradermal adipose loss and dermal fibrosis, and we demonstrate that adiponectin-positive intradermal progenitors give rise to dermal myofibroblasts. PubMed, Arthritis Rheumatol, 12/10/2014. (Also see Skin Fibrosis)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: